Waystar Holding Corp. WAY R2KR3KPHARMA
Company Overview
Waystar Holding Corp. develops a cloud-based software solution for healthcare payments. Its platform offers financial clearance, patient financial care, claim and payer payment management, denials prevention and recovery, clinical integrity and revenue capture, and analytics and reporting solutions. It primarily serves healthcare industry. The company was founded in 2017 and is headquartered in Lehi, Utah.
Why Investors Should Care
Revenue has grown at a 16.0% CAGR over the past five years.
Operating margin of 24.4% supports profitability.
Carries low leverage with a debt-to-equity ratio of 0.37.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $1.10B (+16.5% YoY); net profit $112.09M.
- Trailing 12 Months Year-on-year growth — revenue +18.1%, earnings +16.7%.
- 5-Year Trend Long-term compounding — revenue CAGR 16.0%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 15.97% |
| 1 Year: | 18.10% |
Compounded Profit Growth
| 5 Years: | - |
| 1 Year: | 16.70% |
Stock Price Performance
| 1 Year: | -18.39% |
| 6 Months: | +13.49% |
| 3 Months: | +24.76% |
| 1 Month: | +17.09% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)65.54 · Neutral
P/E of 41.21 is above the sector median of 25.45 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 16.0% over 5 years.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading 29.4% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | WAY Waystar Holding Corp. R2KR3KPHARMA | 28.85 | 41.21 | $5.53B | 0.00% | 4.48% | 3.77% | 15.97% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,273.46 | 42.83 | $1.14T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 263.81 | 30.60 | $635.76B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 285.64 | 80.69 | $504.76B | 2.54% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 418.09 | 26.85 | $375.28B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPXR3KPHARMA | 145.27 | 116.22 | $358.41B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 7 | NVS Novartis AG PHARMA | 151.12 | 22.83 | $287.24B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 171.49 | 25.63 | $265.96B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 673.82 | 36.30 | $249.14B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 195.97M | 197.26M | 224.79M | 234.54M | 240.11M | - | 256.44M | 270.65M | 268.65M | 303.54M | 313.87M | 319.67M |
| Cost of Revenue | - | - | - | - | - | - | 83.34M | 87.04M | 85.14M | 92.64M | 97.03M | - |
| Gross Profit | - | - | - | - | - | - | 173.09M | 183.61M | 183.51M | 210.90M | 216.84M | - |
| Operating Expenses | - | - | - | - | - | - | 107.88M | 118.76M | 123.28M | 151.88M | 136.37M | - |
| Operating Income | 37.19M | 32.22M | 35.19M | 8.24M | 27.15M | - | 65.21M | 64.85M | 60.23M | 59.02M | 80.47M | 76.04M |
| EBITDA | - | - | - | - | - | - | 98.59M | 98.27M | 93.53M | 99.46M | 121.92M | - |
| Interest Expense | - | - | - | - | - | - | 18.90M | 18.25M | 17.52M | 22.87M | 20.65M | - |
| Pretax Income | - | - | - | - | - | - | 46.31M | 46.59M | 42.72M | 36.15M | 59.82M | - |
| Tax Provision | - | - | - | - | - | - | 17.04M | 14.41M | 12.07M | 16.16M | 16.54M | - |
| Net Income | -10.81M | -15.49M | -15.93M | -27.68M | 5.41M | - | 29.27M | 32.18M | 30.65M | 19.99M | 43.28M | 40.87M |
| Diluted EPS | -0.09 | -0.13 | -0.13 | -0.21 | 0.03 | - | 0.16 | 0.18 | 0.17 | 0.10 | 0.22 | 0.21 |
| R&D Expense | 8.25M | 8.97M | 10.32M | 15.90M | 11.08M | - | 11.08M | 12.62M | 12.40M | - | 18.37M | 17.72M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 704.87M | 791.01M | 943.55M | 1.10B |
| Cost of Revenue | - | 214.89M | 249.77M | 315.73M | 348.16M |
| Gross Profit | - | 489.98M | 541.24M | 627.82M | 751.12M |
| Operating Expenses | - | 400.53M | 399.16M | 504.09M | 501.81M |
| Operating Income | - | 89.45M | 142.08M | 123.72M | 249.31M |
| EBITDA | - | 272.62M | 318.55M | 310.36M | 389.85M |
| Interest Expense | - | 155.32M | 205.92M | 146.27M | 77.54M |
| Pretax Income | - | -65.88M | -63.83M | -22.55M | 171.76M |
| Tax Provision | - | -14.42M | -12.50M | -3.42M | 59.67M |
| Net Income | - | -51.45M | -51.33M | -19.12M | 112.09M |
| Diluted EPS | - | -0.31 | -0.31 | -0.13 | 0.61 |
| R&D Expense | - | 32.81M | 35.33M | 48.77M | 54.62M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 4.69B | 4.58B | 4.58B | 5.79B |
| Current Assets | - | 217.90M | 222.05M | 371.04M | 308.41M |
| Cash & Equivalents | - | 64.56M | 35.58M | 182.13M | 61.35M |
| Inventory | - | - | - | - | - |
| Receivables | - | 107.08M | 126.09M | 145.24M | 177.04M |
| Total Liabilities | - | 2.59B | 2.53B | 1.50B | 1.91B |
| Current Liabilities | - | 102.21M | 123.49M | 145.63M | 218.06M |
| Long Term Debt | - | 2.21B | 2.20B | 1.22B | 1.46B |
| Total Debt | - | 2.26B | 2.25B | 1.26B | 1.49B |
| Total Equity | - | 2.11B | 2.05B | 3.08B | 3.88B |
| Shares Outstanding | - | 166.66M | 166.66M | 172.11M | 191.59M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | 102.63M | 51.46M | 169.77M | 309.67M |
| Investing Cash Flow | - | -17.43M | -61.52M | -27.27M | -680.90M |
| Financing Cash Flow | - | -67.06M | -17.15M | 16.65M | 243.45M |
| Capital Expenditure | - | -17.43M | -21.52M | -27.27M | -26.48M |
| Free Cash Flow | - | 85.20M | 29.94M | 142.50M | 283.19M |
| Net Change in Cash | - | 18.14M | -27.21M | 159.15M | -127.77M |
| Share Buybacks | - | 2.45M | 688.00K | 844.00K | 0 |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | 69.5% | 68.4% | 66.5% | 68.3% |
| Operating Margin % | - | 12.7% | 18.0% | 13.1% | 22.7% |
| Net Margin % | - | -7.3% | -6.5% | -2.0% | 10.2% |
| ROE % | - | -2.4% | -2.5% | -0.6% | 2.9% |
| ROCE % | - | 1.9% | 3.2% | 2.8% | 4.5% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Eqt Fund Management S.a R.l. | 12.98% | 24.88M | $663.78M |
| 2 | Canada Pension Plan Investment Board | 9.92% | 19.03M | $507.60M |
| 3 | Blackrock Inc. | 9.09% | 17.44M | $465.18M |
| 4 | FMR, LLC | 7.85% | 15.05M | $401.42M |
| 5 | Bain Capital Investors Llc | 6.91% | 13.24M | $353.34M |
| 6 | Advent International LP | 5.77% | 11.06M | $295.08M |
| 7 | Vanguard Portfolio Management LLC | 3.46% | 6.63M | $176.79M |
| 8 | Goldentree Asset Management LP | 3.21% | 6.16M | $164.35M |
| 9 | Bank of Montreal /CAN/ | 2.71% | 5.19M | $138.45M |
| 10 | Vanguard Capital Management LLC | 2.71% | 5.20M | $138.75M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for WAY
Meta Spent Its Way To Negative Cash Flow. The Stock Noticed. - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMimAFBVV95cUxNMDFKVE83eWFwejRZWGNMOWFici1tNWRUb3VybklsU19oUTRuSW1reDI3VUNMcVNiRzVoNE5jNUJMTF9tYkREaUN2NnVWNkpudlRNTkFzYXRJN0RqOV9fX0ZUaWVfTHpXclFydW9Yb0xDWms5WmJGU2xjSFVzbFFqUXBNSFpGNEpOZUdYLX…
If a Stock Market Crash Is on the Way, Warren Buffett Says This Is the Best Thing Investors Can Do for Their Portfolio - The Motley Fool
<a href="https://news.google.com/rss/articles/CBMimAFBVV95cUxOOE5UbTNvVUVZMWt0WmpUM0NpSVBNVWRjVUFUbTYtbXg1eEMwcnYzMWZLMFZDcUJiRXFKUlMxNnJWYzlzcXZub2lwRkhlUWh0cXRMbTFpV2VEOFdaX091ekl3WDJfWkdlaWZzRmpDTmJpWVAtS29qbTFzaUVESWd1QlhMdktDbFdfYWRiN2…
Meta’s Stock Split Paves Way for Huge AI Financing Deal - Barron's
<a href="https://news.google.com/rss/articles/CBMihwFBVV95cUxQclVZYi1ZSWIzcjFXUVdfWTUzVVh0eUtRRkxmVllWNm1yYzA1Q2s3dVZmVTdPZDlsNjlSR2pfdnpBMkRoZ0Q2UTU4M1ZPajNuekxVZV9tX3dyXzFLNWZ1THFHQmNPZUxiSHNFVkNrRkVMdXhla0hHSVpabEloYndobUp5bFlmN2M?oc=5" …
GE Vernova Stock Rebounds, AI Sell-Off Gives Way To Earnings Focus - TradingView
<a href="https://news.google.com/rss/articles/CBMiwgFBVV95cUxQbnk0X1FXU1JPLVhrT3M0T3RxMnAxYmFJN0VpU1pmWWdNaDAyWG9OYm5OMGdsUVRqQjZZMFIweUFBV3I5MVFkQnZBeV94NUg1WnNrSXJKVHRqWm1TTE01QkRXZm9tOHlodm9zSndEaUd5RnQycG5zU2w5Yi1tZVlJbEh3UW1VdnRhbmw1WF…
India’s Stock Traders Find Another Way to Bet, and Lose, Their Money - Bloomberg.com
<a href="https://news.google.com/rss/articles/CBMiygFBVV95cUxQZ2dJbXVDUlFGRjh2TmRzTk13SVlrM0NHdG1Ub1RCQzY3VnpvRHJDUkxiUnlpbnVOMTROaUoxdEVHVm1TRUtjZzJNaXM1ZmRJWHVCQTc0dHE3U1RKTlhQR0RRZVBJMnRWTGp6b0RMZ2dFWEhVdTZGM1FQTTdYdzM1Rks5b3VhR25KQ0ZGVE…
Gwynne Shotwell’s $300M Trump Accounts pledge shows tax-smart way to donate own company’s stock - Fortune
<a href="https://news.google.com/rss/articles/CBMi7wFBVV95cUxPaENvNzJRMmQycktYTTdJa2Y5ZHBSdGR1bGdxQWxqMG56RmdUTlhteHE2dXdvdjBlcUhoMGFscHUtWm1YbHlvN09QS1FwTTY3MW9VYlJZQjlGVXV3QWpaZ2xCU003NFQ4ZWt3am1LZ21JbDR1MEFqVGl3ZHdGc21rVi0xUW1ndzYwS1oySD…
WAY — Frequently Asked Questions
What is the current share price of Waystar Holding Corp. (WAY)?
As of 2026-10-23 16:27 PDT, Waystar Holding Corp. (WAY) trades at $28.85 on NasdaqGS. Its 52-week range is $17.31 to $40.89.
What is the market capitalisation of WAY?
Waystar Holding Corp. (WAY) has a market capitalisation of $5.53B on NasdaqGS.
What is the P/E ratio of WAY?
WAY trades at a trailing price-to-earnings (P/E) ratio of 41.21. The industry average P/E is 25.45. Its price-to-book (P/B) ratio is 1.25.
What is the return on equity (ROE) of WAY?
WAY has a return on equity (ROE) of 3.77%. Its return on capital employed (ROCE) is 4.48%.
Is WAY a good stock to buy?
This page provides a data-driven analysis of Waystar Holding Corp. (WAY), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.